- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | NIH terminated $1.8B in grants in 40 days under Trump administration: study | ||
| 08.05. | Vor Bio to wind down, halting cell therapy trials and shedding most staff | ||
| 08.05. | NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer's readout | ||
| 08.05. | Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership | ||
| 08.05. | RallyBio cuts deeper, culling 40% of workforce after halting work on lead drug | ||
| 08.05. | GSK posts phase 3 itch data as it closes in on FDA approval | ||
| 08.05. | Takeda shoots down bispecifics bagged in Maverick buyout amid pipeline clearout | ||
| 07.05. | Vivo Capital secures $740M to invest in preclinical and clinical-stage biotechs | ||
| 07.05. | CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing | ||
| 07.05. | Marea rises toward phase 2b after showing antibody cuts remnant cholesterol | ||
| 07.05. | Neurocrine hands back 2 CNS gene therapy programs to Voyager | ||
| 07.05. | C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide | ||
| 06.05. | Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program | ||
| 06.05. | 250 more NIH workers laid off, including cuts at the National Cancer Institute | ||
| 06.05. | Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC | ||
| 06.05. | Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact | ||
| 06.05. | Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner | ||
| 06.05. | PTC crashes as win for Novartis-partnered Huntington's drug fails to convince investors | ||
| 06.05. | Aldeyra posts one hit, one miss for twice-rejected dry eye drug, plans FDA filing | ||
| 05.05. | Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles | ||
| 05.05. | J&J gene therapy fails to improve visual navigation in late-stage rare eye disease trial | ||
| 05.05. | Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline | ||
| 05.05. | Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo | ||
| 05.05. | Deerfield unveils $600M for emerging healthcare therapeutics and tech | ||
| 02.05. | Vertex discontinues AAV research for gene therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .